15,006 Shares in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Bought by Jane Street Group LLC

Jane Street Group LLC purchased a new stake in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) during the third quarter, HoldingsChannel reports. The fund purchased 15,006 shares of the company’s stock, valued at approximately $90,000.

Other institutional investors have also bought and sold shares of the company. Nantahala Capital Management LLC purchased a new stake in shares of Eton Pharmaceuticals in the second quarter valued at $3,095,000. Wasatch Advisors LP bought a new position in Eton Pharmaceuticals during the 3rd quarter valued at about $1,431,000. Aristides Capital LLC purchased a new stake in Eton Pharmaceuticals in the 2nd quarter worth about $658,000. Thompson Siegel & Walmsley LLC bought a new stake in Eton Pharmaceuticals in the second quarter worth about $420,000. Finally, Stonepine Capital Management LLC bought a new position in shares of Eton Pharmaceuticals during the second quarter valued at approximately $362,000. Institutional investors own 27.86% of the company’s stock.

Analyst Ratings Changes

A number of analysts have weighed in on ETON shares. Craig Hallum increased their target price on Eton Pharmaceuticals from $15.00 to $18.00 and gave the stock a “buy” rating in a research note on Wednesday, January 8th. B. Riley assumed coverage on shares of Eton Pharmaceuticals in a report on Friday, January 10th. They set a “buy” rating and a $21.00 price objective for the company. Finally, HC Wainwright lifted their price objective on shares of Eton Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a report on Monday, January 6th.

Eton Pharmaceuticals Stock Down 4.1 %

Eton Pharmaceuticals stock opened at $13.42 on Wednesday. Eton Pharmaceuticals, Inc. has a 52 week low of $3.03 and a 52 week high of $15.00. The stock has a 50-day moving average price of $11.85 and a 200 day moving average price of $7.55. The company has a market capitalization of $349.60 million, a price-to-earnings ratio of -61.00 and a beta of 1.38.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.